153 related articles for article (PubMed ID: 17826684)
1. Dissecting kinase signaling pathways.
Boyle SN; Koleske AJ
Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
[TBL] [Abstract][Full Text] [Related]
2. [Kinase inhibitors and their resistance].
Togashi Y; Nishio K
Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
[TBL] [Abstract][Full Text] [Related]
3. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
4. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
5. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
6. [Problems in the current target therapy of malignancies].
Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
[No Abstract] [Full Text] [Related]
7. Targeting tyrosine kinases in cancer: the second wave.
Baselga J
Science; 2006 May; 312(5777):1175-8. PubMed ID: 16728632
[TBL] [Abstract][Full Text] [Related]
8. Protein kinases as drug targets in cancer.
Arslan MA; Kutuk O; Basaga H
Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targeted therapy].
Stenner-Liewen F; Zippelius A; Pestalozzi BC; Knuth A
Chirurg; 2006 Dec; 77(12):1118-25. PubMed ID: 17109101
[TBL] [Abstract][Full Text] [Related]
10. Type II kinase inhibitors: an opportunity in cancer for rational design.
Blanc J; Geney R; Menet C
Anticancer Agents Med Chem; 2013 Jun; 13(5):731-47. PubMed ID: 23094911
[TBL] [Abstract][Full Text] [Related]
11. Reversing resistance to targeted therapy.
Vidal L; Attard G; Kaye S; De Bono J
J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
13. [Autophagy in hematologic malignancies].
Adachi S
Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
[No Abstract] [Full Text] [Related]
14. Researchers optimistic about sea change in cancer treatment.
Stephenson J
JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
[No Abstract] [Full Text] [Related]
15. Inhibiting tyrosine kinases: successes and limitations.
Arteaga CL
Cancer Biol Ther; 2003; 2(4 Suppl 1):S79-83. PubMed ID: 14508084
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
17. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
Dear R; Wilcken N; Shannon J
Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
[TBL] [Abstract][Full Text] [Related]
18. [Kinase inhibitors].
Yamori T; Kong D
Nihon Rinsho; 2010 Jun; 68(6):1059-66. PubMed ID: 20535956
[TBL] [Abstract][Full Text] [Related]
19. New insights into oncogene addiction found.
Garber K
J Natl Cancer Inst; 2007 Feb; 99(4):264-5, 269. PubMed ID: 17312299
[No Abstract] [Full Text] [Related]
20. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]